Revenue segments as reported by the company.

Software products and services

Drug discovery

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Schrodinger 

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Schrodinger reports robust revenue growth and eyes strategic expansion

Schrodinger delivered strong financial performance in 2022, driven by revenue growth in software and drug discovery segments.
The company's innovative pipeline advancements and focus on neuroscience therapeutics position it well for future growth.
While facing challenges in operating expenses and revenue projections, Schrodinger has opportunities for expansion through partnerships and customer growth.
Capitalizing on existing strengths and addressing challenges will be key for Schrodinger to sustain its growth trajectory and competitive edge.

Schrodinger (SDGR) reports robust Q1 performance and growth opportunities

Schrodinger (SDGR) had a strong Q1 2023, with revenue growth driven by software and drug discovery collaborations.
The company's balance sheet strengthened, but challenges exist with smaller biopharma revenue mix and customer acquisition.
Opportunities lie in capitalizing on existing customer loyalty, potential revenue growth, and continued investments in technology.
Overall, Schrodinger is well-positioned to leverage its strengths and address challenges to drive future growth.

Schrodinger meets revenue expectations, focuses on AI-driven drug discovery

Schrodinger's Q2 2023 earnings call highlighted solid revenue performance, ongoing software revenue discussions, and investments in R&D for platform development. The company showcased strengths in innovative drug discovery methods, progress on proprietary programs, and FDA clearances. Challenges include revenue fluctuations and uncertainties in revenue projections, while opportunities lie in expanding software contracts and leveraging AI for efficiency.

Schrodinger reports solid Q3 growth amidst expense challenges and opportunities

Schrodinger's Q3 performance showed revenue growth driven by software and drug discovery segments, despite increased expenses.
The company's focus on operational efficiency and proprietary programs positions it well for future growth and market expansion.
While facing challenges in managing expenses and uncertainties in partner priorities, Schrodinger remains committed to innovation and value creation.
Opportunities lie in scaling up software usage, evaluating collaboration programs, and leveraging customer interest for revenue growth.

Schrodinger reports strong revenue growth and strategic collaborations in 2023

Schrodinger's financial performance in 2023 reflects growth in total revenue and software revenue, driven by customer expansions and program advancements.
The company's strengths lie in its strategic focus on global biopharma companies, collaborations for AI tools, and the trend towards hosted contracts.
Challenges include forecasting revenue growth, decision-making on program advancement, and factors influencing software revenue dynamics.
Opportunities exist in the increased demand for computational tools, ongoing discussions for software adoption, and the validation of the platform through collaborations.

Schrodinger reports Q1 revenue growth amidst challenges and collaboration opportunities

Schrodinger's Q1 2024 performance reflects revenue growth driven by software revenue, though challenges in China and decreased gross margin were noted.
The company's strengths lie in regained rights to key inhibitors, promising pipeline advancements, and potential growth in ACV and collaboration opportunities.
While facing challenges in profitability and R&D expenses, Schrodinger is well-positioned to capitalize on opportunities in collaborations, funding, and drug development.
Overall, Schrodinger's strategic focus on innovation, partnerships, and pipeline advancement sets the stage for future growth and market expansion.

Schrodinger reports solid Q2 results, eyes strategic growth opportunities

Schrodinger's Q2 performance reflects steady revenue growth and margin improvement, despite operational challenges.
Strategic partnerships, acquisitions, and innovative solutions position Schrodinger for future expansion and market leadership.
Efforts to control expenses, drive revenue growth, and leverage market opportunities will be crucial for Schrodinger's long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ginkgo Bioworks Holdings

Recursion Pharmaceuticals

Recursion Pharmaceuticals just got Nvidia on board with its vision of AI for R&D. Ginkgo Bioworks is pairing AI with laboratory robotics to streamline R&D, too.

3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2023 financial results on Wednesday, August 2, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website, https://ir.schrodinger.com/news-and-.

Schrödinger to Announce Second Quarter 2023 Financial Results on August 2

Schrödinger and Recursion Pharmaceuticals use AI to improve drug development. Neither one has proven its business model to be viable yet.

Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals

Schrödinger's stock is riding the surge of interest in AI. Its drug discovery software is already bringing in money.

This Artificial Intelligence Biotech Stock Is Crushing the Market, but Is It a Buy?

Super Micro Computer

Symbotic Inc

Goldman Sachs recently asserted “that AI adoption could boost productivity growth by 1.5 percentage points per year over a 10-year period.” The venerable firm's estimate shows how tremendously valuable the technology can be to many companies.

Why These 3 Stocks Are the Best Ways to Play AI Right Now

The AZEK Company

Blackstone Group

DoubleVerify Holdings

Interlink Electronics

Trade Desk

Tyler Technologies

Although a topic that arouses myriad emotions, targeting overvalued stocks to sell represents an important component of investing strategy. Since we're in the middle of baseball season, you can't always let sentimental favorites dictate your lineup.

7 Stocks in Hot Water: Dump This Dead Weight as Costs Skyrocket

Schrödinger focuses on drug discovery using an AI platform. The company has already helped bring two therapies to market.

Why Shares of Schrödinger Rose This Week

Aurora Innovation

Exact Sciences

Finding early-stage, revolutionary companies whose market capitalizations can reach $1 trillion can be very lucrative. Just look atAlphabet (NASDAQ:  GOOG, NASDAQ: GOOGL ), Apple (NASDAQ: AAPL ), and Amazon (NASDAQ: AMZN ).

3 Revolutionary Companies With Trillion-Dollar Potential

Schrodinger, Inc. (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Schrodinger, Inc. (SDGR) Surges 6.6%: Is This an Indication of Further Gains?

ExScientia Ltd

Predictive Oncology Inc

A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms.

3 Pharma Stocks That Will Boom Thanks to AI

Despite a slight drop in software sales in 1Q23, attributed to timing issues with multi-year agreements, management revised guidance positively. I am optimistic about the software platform in the latter half of the year when multi-year contracts are up for renewal and new partnerships may arise.

Schrodinger: Reiterate Buy Rating On Strong Software Revenue Growth Ahead

23andMe

Artificial intelligence is becoming an important value-add for collaborations. Some companies are pursuing collaboration-targeted business models.

3 Key Biotech Trends for 2023 And Beyond

Alphabet

iCAD

A few recent news stories highlight the tremendous power of artificial intelligence to improve our world and boost business performance. A doctor says that the technology can be a key means of enabling healthcare to become more personalized and making diagnoses earlier.

3 High-Reward Stocks Riding the AI Boom

PROCEPT BioRobotics Corp

LiveRamp Holdings Inc

Silicon Motion Technology

AbCellera Biologics

Hesai Group

Kymera Therapeutics

While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept some risks.

7 Growth Stocks That Could Double Your Money in 2023

ImmunityBio

Stem, Inc

Darling Ingredients

Elbit Systems

Freeport-McMoRan

Volkswagen AG

With short sellers viciously attacking many popular stocks and Wall Street worrying too much about the macroeconomic outlook, there are a multitude of undervalued growth stocks for investors to buy now. Plus, three recent factors have increased my optimism about growth stocks.

The 7 Most Undervalued Growth Stocks for Your May Buy List

Schrödinger, Inc. (NASDAQ:SDGR ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Affairs Ramy Farid - Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President of R&D, Therapeutics Conference Call Participants Vikram Purohit - Morgan Stanley David Lebowitz - Citi Chris Shibutani - Goldman Sachs Michael Ryskin - Bank of America Operator Thank you for standing by. Welcome to Schrodinger's Conference Call to review First Quarter 2020 Financial Results.

Schrödinger, Inc. (SDGR) Q1 2023 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the first quarter ended March 31, 2023.

Schrödinger Reports Strong First Quarter 2023 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today published its inaugural Corporate Sustainability Report. The report highlights the company's vision and approach to corporate sustainability, summarizes the company's 2022 achievements and discloses key data about its corporate sustainability efforts in alignment with GRI and SASB reporting standards. “At Schrödinger, a.

Schrödinger Publishes Inaugural Corporate Sustainability Report

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its first quarter 2023 financial results on Thursday, May 4, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website, https://ir.schrodinger.

Schrödinger to Announce First Quarter 2023 Financial Results on May 4

AI will be transformative for many industries because the technology allows companies to both save a great deal of money and generate much more revenue. On the savings front, AI can cheaply do many human tasks.

3 Industries Set to Be Transformed by the AI Revolution

Lemonade

Artificial intelligence (AI) is a powerful technology that will enable many businesses to both save money and accelerate growth. As a result, demand for powerful, efficient AI tools is likely to explode, and companies that can deliver them will be quite prosperous.

The 3 Best AI Stocks to Buy Right Now

Today, we put Schrodinger, Inc. in the spotlight as we do a post fourth quarter results assessment on this intriguing developmental and software concern. The company's core software business continues to deliver steady sales growth, while Schrodinger continues to advance an intriguing early stage pipeline.

Schrodinger: An Intriguing Story

Mobileye Global Inc

Medtronic

The Fourth Industrial Revolution refers to the use of multiple advanced technologies, including “artificial intelligence (AI), robotics, [and] the Internet of Things (IoT).” Also in the mix are “faster computer processing,” “biotechnology,” and “Energy capture, storage, and transmission,” Salesforce reported.

3 Tech Stocks to Buy for the Fourth Industrial Revolution

Check Point Software Technologies

Dynatrace Inc

The Street is realizing what computer scientists and many observers have known for years: artificial intelligence has become tremendously powerful and will have a huge impact on our lives. Moreover, AI enables companies to perform tremendously valuable services for each other and consumers.

3 Amazing AI Stocks for Your March Buy List

Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 in January 2021. Schrodinger's artificial intelligence (AI) powered software technology platform utilizes physics-based modeling and sophisticated machine learning algorithms to help clients identify the suitable molecules to treat the desired ailments.

News for Schrodinger Stock (SDGR)